Next-Generation Sequencing (NGS) is a DNA sequencing technology that effectively captures a large amount of genomic information about a tumour, which varies from person to person. Prior to the advent of NGS, tumour genotyping was only performed on specific areas known for frequent cancer mutations. This method was limited in its ability to identify alterations in tumour supressors, whereby a gene alteration may impact its function.

Compared to this approach, NGS can assess multiple genes with a single test, thus revealing the molecular profile of a tumour’s genetic alterations with speed and accuracy. This method of testing is the cornerstone of precision oncology, offering insights to potential therapeutic interventions. Matching a treatment to a tumour molecular profile obtained through NGS is broadly known as targeted therapy.

Today, rapid advancements in NGS have opened new avenues in terms of more effective targeted therapies for cancer patients. However, not everyone may benefit from such cutting-edge next-generation biotherapeutics, many of which are still in their developmental stages.

While your best bet for accessing such therapies may be through their clinical trials, getting enrolled in them can be tricky. Oncologists’ efforts to accurately match their patients to relevant trials according to precise biomarker information are typically hampered by the fact that NGS reports are typically presented in hard copies - which means translating this information into meaningful insights involves a manual process. This results in patients having a limited scope of treatment options, despite having undergone NGS tests.

We’ve created a new solution that allows busy oncologists to fully leverage their patients’ genomic data to improve their clinical outcomes. Oncoshot’s digital platform is designed to allow crucial genomic insights from NGS service provider Roche Foundation Medicine’s (FMI) NGS reports to be well structured and used to match cancer patients to our regularly updated database of global clinical trials, in real time. This information is presented in an easy-to-digest format, revealing matching scores and details that your physician can then discuss with you when deciding your treatment options.

Your anonymised profile will be stored in Oncoshot’s secure system, comprising a genomic database that can help spur research in precision oncology. Ultimately, all this translates to a widened landscape of potentially life-saving treatment options for you. Ask your physician how Oncoshot may improve your cancer treatment journey today.

Upon confirmation of your informed consent, the Roche FMI local office will work with Oncoshot to encrypt your original NGS report into a de-identified profile using clinical and FMI alphanumeric IDs, which is entered onto Oncoshot’s secure system. This digitised profile will then be shared with your physician for review, typically within 24 hours.

A member of the Roche group, FMI develops tests to help doctors understand the genetic profile of patients’ tumors and guide them to effective therapies. All of FMI’s services use their leading comprehensive genomic profiling approach, which broadly analyses the tumour genome to identify clinically relevant alterations. Their genomic profiling services include a tissue-based test and liquid biopsy test respectively for solid tumours, as well as a test for haematological malignancies and sarcomas.